Clinical Trial Details


Research Study Summary

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety of N1539 Following Major Surgery


This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, evaluation of the safety of N1539 in adult subjects undergoing major surgery.

To Learn more

CW ID: 216182
Date Last Changed: June 16, 2016

Clinical Trial Snapshot

Both Male and Female
18 to 80 Years
Overall Status
Lead Sponsor
Recro Pharma
Facility Type


Inclusion Criteria:
  • Subject must be planned to undergo major elective surgery, and be expected to require intravenous analgesia and remain in an inpatient setting for at least 48 hours.
  • Have a body mass index ≤38 kg/m2
Exclusion Criteria:
  • Have a known allergy or hypersensitivity to meloxicam or any excipient of N1539, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Be scheduled to undergo cranial surgery, open heart procedure, any type of coronary artery bypass graft, organ transplant, cancer related surgery, or any other surgical procedure in which NSAIDs are contraindicated.
  • Planned or actual admission to the intensive care unit at any time during study participation.
  • Have a history of myocardial infarction within the preceding 12 months.
  • Have history of or positive test results for HIV, or hepatitis B or C.


Rachel Karlnoski
University of South Florida - South Tampa Center for Advanced Healthcare
2 Tampa General Circle
Tampa, FL 33606
Phone: 813-844-4133

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.